Recent Updates
Recently added Catalysts
ELUT Positive Sentiment

Elutia Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

Key Takeaway: Elutia Inc. announced the granting of 378,000 stock options to two new employees under its 2026 Inducement Award Plan. These options, approved by the Compensation Committee, vest over four years and have an exercise price of $0.93 per share. This move aligns with Nasdaq regulations and supports the company's growth strategy.

Market Sentiment Analysis

POSITIVE FACTORS

  • Elutia granted 378,000 stock options to new employees.
  • The awards comply with Nasdaq Listing Rule 5635(c)(4).
  • The stock options have a favorable exercise price of $0.93.

Full Press Release Details

GAITHERSBURG, Md., Nov. 17, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) ("Elutia" or the "Company"), a drug delivery company built to stop surgical infections, today announced that it granted equity awards on November 10, 2026 to two new employees as inducement awards under the Elutia Inc. 2026 Inducement Award Plan (the “Plan”). The awards were approved by the independent Compensation Committee of the Board of Directors and were granted in accordance with Nasdaq Listing Rule 5635(c)(4).
Under the Plan, the two new employees received an aggregate of 378,000 non-qualified stock options (the “Options”). The Options vest 25% on the first anniversary of their vesting commencement dates, with the balance vesting in equal monthly installments over the following three years. Vesting is subject to each recipient’s continued employment through the applicable vesting date. The Options had an exercise price of $0.93 per share, the closing price of Elutia’s common stock on the Nasdaq Capital Market on November 10, 2026, the grant date. The Options are subject to the terms and conditions of the Plan and the applicable stock option agreement.
About Elutia Elutia Inc. (Nasdaq: ELUT) is a drug delivery company built to stop surgical infections. The Company developed and launched EluPro, the first antibiotic-eluting bioenvelope designed to protect patients receiving pacemakers and defibrillators, and in 2025 sold that business to Boston Scientific Corporation. Elutia’s lead program, NXT-41x, builds on the same drug-eluting platform and is designed to deliver two powerful antibiotics directly to the surgical site, stopping infection before it starts. Elutia’s mission is humanizing medicine so patients can thrive without compromise. For more information, visit www.Elutia.com.

Investors: Elutia Investor Relations ir@elutia.com

Frequently Asked Questions

What are the inducement awards granted by Elutia?

Elutia granted 378,000 stock options to two new employees.

What is the exercise price of the stock options?

The exercise price of the options is $0.93 per share.

How do the stock options vest?

The options vest 25% after one year, then monthly over three years.

Which Nasdaq rule governs these awards?

The awards are granted under Nasdaq Listing Rule 5635(c)(4).

Last updated: Nov 17, 2026